PCMG Sustainability Action Group
The PCMG Sustainability Action Group is committed to driving positive change in the pharmaceutical and clinical outsourcing sectors by embedding sustainability into everyday business practices. Guided by key principles of resilience, well-being, and global responsibility, the group brings together industry professionals to translate sustainability goals into meaningful action. By fostering collaboration and sharing best practices, the group seeks to reduce environmental impact, support resource-efficient clinical development, and help organisations—especially small biotech companies—establish feasible sustainability frameworks.
To achieve its mission, the PCMG Sustainability Action Group has initiated several practical tools and resources. These include a Start-Up Package to help companies integrate sustainability into their operations, contract wording recommendations to reinforce commitments across partnerships, and a sustainability questionnaire designed to facilitate dialogue with stakeholders. Additionally, a survey will capture current sustainability initiatives within the industry, inspiring further progress. By empowering organisations and individuals to take action, the group aims to build a more sustainable future for the pharmaceutical sector and beyond.
Sustainability Action Group Insights Session 1
March 2025
PCMG Sustainability Action Group Members
Thierry Escudier Pistoia Alliance
Thierry Escudier is a senior leader in Clinical Operations with a strong focus on digital innovation and patient centricity. A PCMG member since 2004 and an independent consultant since 2021, he serves as a Strategic Leader for the Pistoia Alliance, a global non-profit dedicated to advancing innovation in life sciences and healthcare R&D. Thierry leads the Pistoia Alliance project on the Carbon Footprint of Clinical Trials, a collaborative effort involving 10 pharmaceutical companies and six CROs to develop a standardized approach for evaluating the environmental impact of decentralized clinical trials (DCTs).
Stuart McGuire Veramed
Stuart McGuire has over 20 years of pharmaceutical experience and leads Veramed’s growth as a premier biometrics CRO partner. As Veramed’s Environmental Ambassador, he drives the company’s B Corp certification and leads the cross-company Environment ‘Hive’. Additionally, Stuart is an active member of the PCMG ESG committee, where he supports sustainability initiatives and contributes to the PCMG Annual Assembly.
Inga Nachreiner argenx BV
Inga Nachreiner is a senior Clinical Sourcing Manager at argenx BV, specializing in innovative clinical study outsourcing to enhance patient centricity and ensure fast, high-quality delivery. A PCMG member since 2008 and a committee member since 2023, she holds a PhD in Molecular Biology and Pharmaceutical Product Development. With 15 years of experience in Clinical Development and Procurement across Global Pharma and BioTech, she is also a dedicated mother of three, navigating the challenges of a changing climate.
Carly Santer Bayer
Carly has worked in clinical research for 15 years and has an interest in how healthcare has evolved in response to our environment, along with how this will impact future generations,. Over time, this has developed into a focus on sustainability in clinical research with the goals to reduce the negative impact that healthcare has on the environment and increase global equity in access to healthcare. She was Bayer’s first Impact Officer in 2023, where she aligned her objectives with the framework of the Well-being of Future Generations (Wales) Act 2015 and currently leads a team optimising Bayer’s global clinical trial design for sustainability, which includes reducing waste and carbon emissions and increasing diversity in clinical trials. Carly holds a number of sustainability advisory roles across a range of sectors, she is an alumni of the Cambridge Institute for Sustainability Leadership (CISL) and a Fellow of the Royal Society of Arts (RSA).
Andrew Goodvin
After completing his PhD Andrew joined the pharmaceutical industry, working in clinical research for over 30 years, in both project and functional management roles, leading teams across the globe. During the COVID-19 pandemic Andrew developed a passion for ornithology, this leading to a deeper understanding of environmental matters. Andrew is an alumni of the Cambridge Institute for Sustainable Leadership (CISL) and passionate about raising awareness of the potential devastation of our planet and ‘triggering’ others to look-up and make a change to their individual and collective behaviours.
Sandra Johnson
Sandra has over 20 years experience in life science project management, outsourcing and sustainability. She is a member of the PCMG and one of the newer members of the Sustainability Action Group. Sandra is passionate about the environment and particularly enjoys aligning teams to ensure optimal impact across clinical trial ecosystems in low and middle income countries.